Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics
Published: Aug 2014 | Publisher: Current Partnering | Pages: 695SUMMARY
The Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the collaborative R&D partnering deals and agreements entered into by the worlds leading healthcare companies
TABLE OF CONTENTS
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in collaborative R&D dealmaking
2.1. Introduction
2.2. Definition of collaborative R&D partnering
2.3. Success factors for collaborative R&D deals
2.4. When collaborative R&D can be useful
2.5. Attributes of collaborative R&D deals
2.6. Trends in collaborative R&D deals since 2009
2.7. The future of collaborative R&D deals
Chapter 3 – Overview of collaborative R&D deal structure
3.1. Introduction
3.2. Pure versus multi-component collaborative R&D deals
3.3. Pure collaborative R&D agreement structure
3.3.1. Example collaborative R&D agreements
3.3.1.a. Case study 1: Marinus Pharmaceuticals - NovaMedica – June 2013
3.3.1.b. Case study 2: Idenix Pharmaceuticals – Janssen Pharmaceuticals – January 2013
3.4. Collaborative R&D as part of a wider alliance agreement
3.4.1. Example collaborative R&D agreements and their licensing clauses
3.4.1.a. Case study 3: 4D Molecular Therapeutics – UniQure – January 2014
3.4.1.b. Case study 4: Kyowa Hakko Kirin – Ultragenyx Pharmaceuticals – September 2013
3.4.2. Example licensing option right clauses in collaborative R&D deals
3.4.2.a. Case study 5: Forest Laboratories - Trevena – May 2013
3.4.2.b. Case study 6: Abbvie – Receptos – March 2013
Chapter 4 – Leading collaborative R&D deals
4.1. Introduction
4.2. Top collaborative R&D deals by value
4.3. Most active collaborative R&D dealmakers
4.3.1 Most active collaborative R&D dealmakers by therapy
4.3.2. Most active collaborative R&D dealmakers by stage of development
4.4. Bigpharma collaborative R&D deal activity
4.4. Bigbiotech collaborative R&D deal activity
Chapter 5 – Collaborative R&D deal term benchmarks
5.1. Introduction
5.2. Collaborative R&D headline values
5.5.2. Collaborative R&D upfront payments
5.2.3. Collaborative R&D milestone payments
5.2.4. Collaborative R&D royalty rates
Chapter 6 – Bigpharma collaborative R&D deals
6.1. Introduction
6.2. How to use collaborative R&D deals
6.3. Big pharma collaborative R&D agreement listings
Chapter 7 – Bigbiotech collaborative R&D deals
7.1. Introduction
7.2. How to use collaborative R&D deals
7.3. Big biotech collaborative R&D agreement listings
Chapter 8 – Collaborative R&D contract directory 2009-2014
8.1. Introduction
8.2. Company A-Z
8.3. By therapy area
8.4. By stage of development at signing
8.5. By technology area
Appendices
Appendix – Resources
Appendix – Deal type definitions
Appendix 1 – Collaborative R&D dealmaking - by financial disclosure
Appendix 2 – Collaborative R&D - by companies A-Z
Appendix 3 – Collaborative R&D - by stage of development
Appendix 4 – Collaborative R&D - by therapeutic target
Appendix 5 – Collaborative R&D - by technology type
About Wildwood Ventures
Current Partnering
Current Agreements
TABLE OF FIGURES
Figure 1: Definition of collaborative R&D
Figure 2: Situations where collaborative R&D can prove useful
Figure 3: Key attributes of a collaborative R&D deal
Figure 4: Trends in collaborative R&D deal announcements, 2009-2014
Figure 5: Collaborative R&D deals signed at each phase of development, 2009-2014
Figure 6: Collaborative R&D deals by therapy area, 2009-2014
Figure 7: Collaborative R&D agreements – what should a contract include?
Figure 8: Components of the collaborative R&D deal structure
Figure 9: Top collaborative R&D deals by value since 2009
Figure 10: Most active collaborative R&D dealmakers 2009-2014
Figure 11: Most active collaborative R&D dealmakers 2009-2014 by therapy
Figure 12: Most active collaborative R&D dealmakers 2009-2014 – by stage of development
Figure 13: Bigpharma – top 50 – collaborative R&D deals 2009 to 2014
Figure 14: Bigpharma collaborative R&D deal frequency - 2009 to 2014
Figure 15: Bigbiotech – top 50 – collaborative R&D deals 2009 to 2014
Figure 16: Bigbiotech collaborative R&D deal frequency - 2009 to 2014
Figure 17: Collaborative R&D deal headline value distribution, US$million – discovery stage
Figure 18: Collaborative R&D deal headline value distribution, US$million – preclinical stage
Figure 19: Collaborative R&D deal headline value distribution, US$million – phase I stage
Figure 20: Collaborative R&D deal headline value distribution, US$million – phase II stage
Figure 21: Collaborative R&D deal headline value distribution, US$million – phase III stage
Figure 22: Collaborative R&D deal headline value distribution, US$million – regulatory stage
Figure 23: Collaborative R&D deal headline value distribution, US$million – marketed stage
Figure 24: Summary median Collaborative R&D headline value by stage of development, 2009-2014
Figure 25: Collaborative R&D deal upfront payment distribution, US$million – discovery stage
Figure 26: Collaborative R&D deal upfront payment distribution, US$million – preclinical stage
Figure 27: Collaborative R&D deal upfront payment distribution, US$million – phase I stage
Figure 28: Collaborative R&D deal upfront payment distribution, US$million – phase II stage
Figure 29: Collaborative R&D deal upfront payment distribution, US$million – phase III stage
Figure 30: Collaborative R&D deal upfront payment distribution, US$million – regulatory stage
Figure 31: Collaborative R&D deal upfront payment distribution, US$million – marketed stage
Figure 32: Summary median collaborative R&D upfront payments by stage of development, 2009-2014
Figure 33: Collaborative R&D deal milestone distribution, US$million – discovery stage
Figure 34: Collaborative R&D deal milestone distribution, US$million – preclinical stage
Figure 35: Collaborative R&D deal milestone distribution, US$million – phase I stage
Figure 36: Collaborative R&D deal milestone distribution, US$million – phase II stage
Figure 37: Collaborative R&D deal milestone distribution, US$million – phase III stage
Figure 38: Collaborative R&D deal milestone distribution, US$million – regulatory stage
Figure 39: Collaborative R&D deal milestone distribution, US$million – marketed stage
Figure 40: Collaborative R&D deals with royalty rates, %
Figure 41: Collaborative R&D deal royalty rate distribution, US$million – discovery stage
Figure 42: Collaborative R&D deal royalty rate distribution, US$million – preclinical stage
Figure 43: Collaborative R&D deal royalty rate distribution, US$million – phase I stage
Figure 44: Collaborative R&D deal royalty rate distribution, US$million – phase II stage
Figure 45: Collaborative R&D deal royalty rate distribution, US$million – phase III stage
Figure 46: Collaborative R&D deal royalty rate distribution, US$million – regulatory stage
Figure 47: Collaborative R&D deal royalty rate distribution, US$million – marketed stage
Figure 48: Summary median collaborative R&D royalty rate by stage of development, 2009-2014
Figure 49: Online partnering resources
Figure 50: Deal type definitions
Chapter 1 – Introduction
Chapter 2 – Trends in collaborative R&D dealmaking
2.1. Introduction
2.2. Definition of collaborative R&D partnering
2.3. Success factors for collaborative R&D deals
2.4. When collaborative R&D can be useful
2.5. Attributes of collaborative R&D deals
2.6. Trends in collaborative R&D deals since 2009
2.7. The future of collaborative R&D deals
Chapter 3 – Overview of collaborative R&D deal structure
3.1. Introduction
3.2. Pure versus multi-component collaborative R&D deals
3.3. Pure collaborative R&D agreement structure
3.3.1. Example collaborative R&D agreements
3.3.1.a. Case study 1: Marinus Pharmaceuticals - NovaMedica – June 2013
3.3.1.b. Case study 2: Idenix Pharmaceuticals – Janssen Pharmaceuticals – January 2013
3.4. Collaborative R&D as part of a wider alliance agreement
3.4.1. Example collaborative R&D agreements and their licensing clauses
3.4.1.a. Case study 3: 4D Molecular Therapeutics – UniQure – January 2014
3.4.1.b. Case study 4: Kyowa Hakko Kirin – Ultragenyx Pharmaceuticals – September 2013
3.4.2. Example licensing option right clauses in collaborative R&D deals
3.4.2.a. Case study 5: Forest Laboratories - Trevena – May 2013
3.4.2.b. Case study 6: Abbvie – Receptos – March 2013
Chapter 4 – Leading collaborative R&D deals
4.1. Introduction
4.2. Top collaborative R&D deals by value
4.3. Most active collaborative R&D dealmakers
4.3.1 Most active collaborative R&D dealmakers by therapy
4.3.2. Most active collaborative R&D dealmakers by stage of development
4.4. Bigpharma collaborative R&D deal activity
4.4. Bigbiotech collaborative R&D deal activity
Chapter 5 – Collaborative R&D deal term benchmarks
5.1. Introduction
5.2. Collaborative R&D headline values
5.5.2. Collaborative R&D upfront payments
5.2.3. Collaborative R&D milestone payments
5.2.4. Collaborative R&D royalty rates
Chapter 6 – Bigpharma collaborative R&D deals
6.1. Introduction
6.2. How to use collaborative R&D deals
6.3. Big pharma collaborative R&D agreement listings
Chapter 7 – Bigbiotech collaborative R&D deals
7.1. Introduction
7.2. How to use collaborative R&D deals
7.3. Big biotech collaborative R&D agreement listings
Chapter 8 – Collaborative R&D contract directory 2009-2014
8.1. Introduction
8.2. Company A-Z
8.3. By therapy area
8.4. By stage of development at signing
8.5. By technology area
Appendices
Appendix – Resources
Appendix – Deal type definitions
Appendix 1 – Collaborative R&D dealmaking - by financial disclosure
Appendix 2 – Collaborative R&D - by companies A-Z
Appendix 3 – Collaborative R&D - by stage of development
Appendix 4 – Collaborative R&D - by therapeutic target
Appendix 5 – Collaborative R&D - by technology type
About Wildwood Ventures
Current Partnering
Current Agreements
TABLE OF FIGURES
Figure 1: Definition of collaborative R&D
Figure 2: Situations where collaborative R&D can prove useful
Figure 3: Key attributes of a collaborative R&D deal
Figure 4: Trends in collaborative R&D deal announcements, 2009-2014
Figure 5: Collaborative R&D deals signed at each phase of development, 2009-2014
Figure 6: Collaborative R&D deals by therapy area, 2009-2014
Figure 7: Collaborative R&D agreements – what should a contract include?
Figure 8: Components of the collaborative R&D deal structure
Figure 9: Top collaborative R&D deals by value since 2009
Figure 10: Most active collaborative R&D dealmakers 2009-2014
Figure 11: Most active collaborative R&D dealmakers 2009-2014 by therapy
Figure 12: Most active collaborative R&D dealmakers 2009-2014 – by stage of development
Figure 13: Bigpharma – top 50 – collaborative R&D deals 2009 to 2014
Figure 14: Bigpharma collaborative R&D deal frequency - 2009 to 2014
Figure 15: Bigbiotech – top 50 – collaborative R&D deals 2009 to 2014
Figure 16: Bigbiotech collaborative R&D deal frequency - 2009 to 2014
Figure 17: Collaborative R&D deal headline value distribution, US$million – discovery stage
Figure 18: Collaborative R&D deal headline value distribution, US$million – preclinical stage
Figure 19: Collaborative R&D deal headline value distribution, US$million – phase I stage
Figure 20: Collaborative R&D deal headline value distribution, US$million – phase II stage
Figure 21: Collaborative R&D deal headline value distribution, US$million – phase III stage
Figure 22: Collaborative R&D deal headline value distribution, US$million – regulatory stage
Figure 23: Collaborative R&D deal headline value distribution, US$million – marketed stage
Figure 24: Summary median Collaborative R&D headline value by stage of development, 2009-2014
Figure 25: Collaborative R&D deal upfront payment distribution, US$million – discovery stage
Figure 26: Collaborative R&D deal upfront payment distribution, US$million – preclinical stage
Figure 27: Collaborative R&D deal upfront payment distribution, US$million – phase I stage
Figure 28: Collaborative R&D deal upfront payment distribution, US$million – phase II stage
Figure 29: Collaborative R&D deal upfront payment distribution, US$million – phase III stage
Figure 30: Collaborative R&D deal upfront payment distribution, US$million – regulatory stage
Figure 31: Collaborative R&D deal upfront payment distribution, US$million – marketed stage
Figure 32: Summary median collaborative R&D upfront payments by stage of development, 2009-2014
Figure 33: Collaborative R&D deal milestone distribution, US$million – discovery stage
Figure 34: Collaborative R&D deal milestone distribution, US$million – preclinical stage
Figure 35: Collaborative R&D deal milestone distribution, US$million – phase I stage
Figure 36: Collaborative R&D deal milestone distribution, US$million – phase II stage
Figure 37: Collaborative R&D deal milestone distribution, US$million – phase III stage
Figure 38: Collaborative R&D deal milestone distribution, US$million – regulatory stage
Figure 39: Collaborative R&D deal milestone distribution, US$million – marketed stage
Figure 40: Collaborative R&D deals with royalty rates, %
Figure 41: Collaborative R&D deal royalty rate distribution, US$million – discovery stage
Figure 42: Collaborative R&D deal royalty rate distribution, US$million – preclinical stage
Figure 43: Collaborative R&D deal royalty rate distribution, US$million – phase I stage
Figure 44: Collaborative R&D deal royalty rate distribution, US$million – phase II stage
Figure 45: Collaborative R&D deal royalty rate distribution, US$million – phase III stage
Figure 46: Collaborative R&D deal royalty rate distribution, US$million – regulatory stage
Figure 47: Collaborative R&D deal royalty rate distribution, US$million – marketed stage
Figure 48: Summary median collaborative R&D royalty rate by stage of development, 2009-2014
Figure 49: Online partnering resources
Figure 50: Deal type definitions
My Basket
You have no items in your shopping cart.
Need Help?
Unsure which report to purchase or have a query regarding a report, please contact us and we'll be glad to help.
Contact our Report Store Team
Email us or call
+44 (0)1904 435190 Europe
+1 (813) 971.8273 US
- Most Viewed